Computer vision syndrome among university students during the corona virus pandemic

Computer vision syndrome (CVS) is a group of eye and visual problems related to computer use and it is associated with near work. The aim is to determine CVS prevalence, major complaints and main preventive practices among the University of Jordan students after the COVID-19 pandemic era. We conducted a cross-sectional descriptive study using an online pre-tested structured questionnaire. Each participant completed the questionnaire before and after the COVID-19 pandemic and the results were compared. A total of 634 students were included in the study. A high prevalence of CVS was observed after the COVID 19 era. The most significant risk factors for the presence of CVS before and after the pandemic were daily hours use of E-device for studying (p<0.001) and the use of glasses or contact lens (p<0.05). Brightness adjustment, keeping sufficient distance away from the device, taking breaks, increasing the screen font size and using eye drops were the most significant preventive measures taken by students before and after the pandemic (p<0.05). It is a necessity to raise awareness among students regarding computer related health problems and preventive measures need to be adopted to address the risk factors

Coronavirus disease 2019 (COVID-19): a brief overview of features and current treatment

Since the report of the first cases of pneumonia caused by SARS-CoV-2 in December 2019, COVID-19 has become a pandemic and is globally overwhelming healthcare systems. The symptoms of COVID-19 vary from asymptomatic infection to severe complicated pneumonia with acute respiratory distress syndrome (ARDS) and multiple organ failure leading to death. The estimated case-fatality rate among infected patients in Wuhan, the city where the first case appeared, was 1.4%, with 5.1 times increase in the death rate among those aged above 59 years than those aged 30–59 years. In the absence of a proven effective and licensed treatment, many agents that showed activity against previous coronavirus outbreaks such as SARS and MERS have been used to treat SARS-CoV-2 infection. The SARS-CoV-2 is reported to be 80% homologous with SARS-CoV, and some enzymes are almost 90% homologous. Antiviral drugs are urgently required to reduce case fatality-rate and hospitalizations to relieve the burden on healthcare systems worldwide. Randomized controlled trials are ongoing to assess the efficacy and safety of several treatment regimens

Coronavirus Disease 2019 (COVID-19): A Brief Overview of Features and Current Treatment

Since the report of the first cases of pneumonia caused by SARS-CoV-2 in December 2019, COVID-19 has become a pandemic and is globally overwhelming healthcare systems. The symptoms of COVID-19 vary from asymptomatic infection to severe complicated pneumonia with acute respiratory distress syndrome (ARDS) and multiple organ failure leading to death. The estimated case-fatality rate among infected patients in Wuhan, the city where the first case appeared, was 1.4%, with 5.1 times increase in the death rate among those aged above 59 years than those aged 30–59 years. In the absence of a proven effective and licensed treatment, many agents that showed activity against previous coronavirus outbreaks such as SARS and MERS have been used to treat SARS-CoV-2 infection. The SARS-CoV-2 is reported to be 80% homologous with SARS-CoV, and some enzymes are almost 90% homologous. Antiviral drugs are urgently required to reduce case fatality-rate and hospitalizations to relieve the burden on healthcare systems worldwide. Randomized controlled trials are ongoing to assess the efficacy and safety of several treatment regimens